18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

Synapse

Volumn 43, Issue 3, 2002, Pages 201-207

  Ceravolo, Roberto ^a,b,c,d   Piccini, Paola ^a   Bailey, Dale L ^a   Jorga, Karin M ^c   Bryson, Helen ^c   Brooks, David J ^a,b  

^a MRC Cyclotron Unit   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d UNIVERSITY OF PISA   (Italy)

Author keywords

COMT inhibition; Dopamine storage; Fluorodopa positron emission tomography; Parkinson's disease; Tolcapone

Indexed keywords

AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE; DOPA; FLUORINE 18; PLACEBO; TOLCAPONE; BENZOPHENONE DERIVATIVE; DIAGNOSTIC AGENT; DOPAMINE; DRUG DERIVATIVE; ENZYME INHIBITOR; FLUORODOPA F 18; NITROPHENOL;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEVICE; FEMALE; HUMAN; MALE; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; CAUDATE NUCLEUS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; METABOLISM; MIDDLE AGED; NEOSTRIATUM; NERVE CELL; PATHOPHYSIOLOGY; PUTAMEN; SCINTISCANNING;

AGED; BENZOPHENONES; CATECHOL O-METHYLTRANSFERASE; CAUDATE NUCLEUS; CROSS-OVER STUDIES; DIHYDROXYPHENYLALANINE; DOPAMINE; ENZYME INHIBITORS; HUMANS; MIDDLE AGED; NEOSTRIATUM; NEURONS; NITROPHENOLS; PARKINSON DISEASE; PUTAMEN; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036489157     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10034     Document Type: Article

References (37)

1. Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro-40-7592
2. Randomized placebo-controlled study of tolcapone in patients with fluctuating Parkinson's disease treated with levodopa-carbidopa
3. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients
4. 3D acquisition and reconstruction in positron emission tomography
5. Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
6. Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihidroxy-phenylalanine 8[18F]-FDOPA) in humans
7. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP induced parkinsonism in monkeys
8. Effects of monoamine oxydase and catechol-O-methyltransferase inhibition on dopamine turnover: A PET study with 6-[18F]L-DOPA
9. Dopamine visualized in the basal ganglia of living man
10. Blood-brain barrier transport and cerebral utilisation of dopa in living monkeys
11. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease
12. Graphical analysis of 6-fluoro-L-dopa trapping: Effect of inhibition of catechol-O-methyl-transferase
13. Fluorodopa positron emission tomography with an inhibitor of catecholo-O-methyltransferase: Effect of the plasma 3-O-methyldopa fraction on data analysis
14. Effect of tolcapone on benserazide pharmacokinetics
15. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum
16. Tolcapone improves motor function and reduces levodopa requirements in patients with Parkinson's disease experiencing motor fluctuations: A multicentre, double-blind, randomized, placebo-controlled trial
17. [18F]-6-Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR-462)
18. Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: Implications for compartmental modelling and clinical usefulness
19. Acute administration of levodopa/benserazide and tolcapone, a COMT inhibitor, in Parkinson's disease
20. Nigrostriatal function in humans studied with positron emission tomography
21. Plasma DOPA concentrations after different preparations of levodopa in normal subjects
22. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-Dopa and dopamine in rats
23. Pharmacokinetics and pharmacodynamics of L-dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease
24. Tolcapone and hepatotoxic effects
25. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data
26. Cerebral 6-[18F]fluoro-L-dopa uptake in rhesus monkey: Pharmacological influence of aromatic amino acid decarboxylase(AAAD) and catechol-O-methyltransferase (COMT) inhibition
27. Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: A double-blind, placebo-controlled, multicentre trial
28. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients
29. Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging
30. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: Implications for levodopa therapy of Parkinson's disease
31. The presence of catechol-O-methyltransferase activity in separately cultured cerebromicrovascular endothelial and smooth muscle cells
32. Central action of benserazide after COMT inhibition demonstrated in vivo by PET
33. Comparison of two new inhibitors of catechol-O-methyltransferase on striatal dopamine metabolism: A microdialysis study in rats
34. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease
35. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase
36. Potent COMT inhibition by Ro 40-7592 in the periphery ad in the brain